Daniel J. Becker
Independent DirectorDr. Daniel J. Becker, also known as Dan, M.D., Ph.D. is Independent Director of Zura Bio Limited from May 21, 2025. He is Director at Areteia Therapeutics, Inc from February 15, 2024. He served as Director at Hemab Therapeutics Holdings, Inc. Until April 2026. He serves as Director at Perfuse Therapeutics, Inc. He serves as a Director of GRO Biosciences Inc. since July 2024. He was an Independent Director at Acelyrin, Inc. since September 09, 2022 until May 2025. He serves as Managing Director of Access Biotechnology. He was Director of Hemab ApS since February 21, 2023 to April 2026. Dr. Becker was Director at DTx Pharma, LLC since March 2021 to July 2023. He is a Partner at Access Biotechnology, the biopharmaceutical investing arm of Access Industries since August 2019. He serves as Director of Day One Biopharmaceuticals, Inc. and Day One Biopharmaceuticals Holding Co LLC since December 2019. He serves as Director at Matchpoint Therapeutics, Inc. He served as Director at Day One Biopharmaceuticals, Inc. since December 2019 until 2024. He was a Director at Pandion Therapeutics, Inc. (formerly known as Pandion Therapeutics Holdco LLC) since March 2020 to April 2021. Dr. Becker has been a biotechnology Principal of Access Industries since August 2019. He served as a Principal at New Leaf Venture Partners from January 2015 to May 2019. Previously, he was an Associate at the firm. Dr. Becker joined the New Leaf Venture Partners in 2015 and focuses on Biopharmaceutical. Prior to joining New Leaf, he was a Principal at the Boston Consulting Group from August 2009 to January 2015, where he was a core Member of their Health Care practice and led projects across the health care sector with an emphasis on biopharma R&D. Prior to BCG, Dr. Becker was a Research Fellow at Harvard Medical School and from 2006 to 2009 trained clinically in internal medicine and nephrology at Brigham and Womens Hospital and Massachusetts General Hospital. He serves as Director of Pandion Operations, Inc. (formerly known as Pandion Therapeutics, Inc.) since April 2020. He served as Director at Principia Biopharma Inc. since 2017 until September 28, 2020. He serves as a Director of Neurana Pharmaceuticals, Inc. He has co-authored multiple scientific publications in peer-reviewed journals, including Nature Genetics and the Journal of Cell Biology. He is Board-certified in Internal Medicine. He serves as Director of Mariana Oncology, Inc. (formerly known as Curie Therapeutics, Inc.). from September 15, 2021. Dr. Becker graduated summa cum laude with a B. S. in Physiology from the University of Illinois at Urbana-Champaign and obtained both his M. D. and Ph. D. (Cellular and Molecular Biology) degrees from the University of Michigan.
Positions
- Company NameZura Bio LimitedStock CodeZURAPositionIndependent DirectorColleagues
- SCSandeep Chidambar KulkarniCo-Founder, CEO & Director
- ADAmit D. MunshiIndependent Chairman
- KAKimberly Ann DavisCOO, Chief Legal Officer & Corporate Secretary
- KNKiran NistalaChief Medical Officer & Head of Development
- MMMarlyn MathewVP of Finance & Accounting and Principal Financial & Accounting Officer
- GWGary WhaleChief Technology Officer
- SJSteven J. SchochIndependent Director
- PSParvinder Singh ThiaraIndependent Director
